Additional research to the "Phase II Nab-Paclitaxel + Ramucirumab + Nivolumab in Unresectable Advanced or Recurrent Gastric Cancer Refractory to First-Line Therapy Including Pyrimidine Fluoride, Platinum, and Anti-PD-1/PD-L1 Antibodies (PADDLE)" study
Not Applicable
Recruiting
- Conditions
- Advanced gastric cancer
- Registration Number
- JPRN-UMIN000050765
- Lead Sponsor
- ational Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method